DRUG INTERACTION
Naivex joins with drugs released through OCT2 or MATE1 (dofetilide or metformin), causes elongation of plasma concentration of these medicines. Naivex joined with etravirine causes lessen in plasma dissemination of Dolutegravir. Naivex at the same time used with threatening to mycobacterials, against convulsants or herbal product like st. Johns wort causes depletion in plasma dissemination of Dolutegravir. Dolutegravir is a substrate of UGT1A3, UGT1A9, BCRP and P-gp transporters. Naivex joined with the prescription which prohibits these synthetic compounds or transporters cause, growing the plasma concentration of Dolutegravir.Naivex tablets is specialist use with non-nucleoside reverse transcriptase inhibitors; causing utilization of effect of union of Naivex. If Naivex tablets are solidifies with protease inhibitor causes decreasing in plasma appropriation of Dolutegravir.
​
SAFETY MEASURES
An anaphylactic response: This may happen as a result of contraindication
Nonappearance of virological response due to drug interaction: The Resistance of Naivex may occur in a patient in the midst of going with use other drugs.
Safe reconstitution issue: Some sheltered modifying illness is occurred in the midst of the fundamental period of threatening to retro viral treatment
Safe reconstitution issue: Some sheltered modifying illness is occurred in the midst of the fundamental period of threatening to retro viral treatment
​
MISSED DOSE
Naivex, are unfriendly to retroviral prescription, if missed measurements occurred over the traverse of treatment, must be direct with therapeutic master and take after the rule as indicated by their suggestion. On the other way, the missed dose should be avoided and take the standard schedule.
The pregnancy classification of Dolutegravir is B Using Naivexin pregnancy condition with caution, essentially in the wake of knowing the danger parts to the hatchling of these things In Some patient’s placental change happens, in such conditions stop the utilization of these products.